Navigation Links
Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Date:6/12/2013

umab

Brodalumab is a highly-selective human monoclonal antibody that binds to and blocks signaling via the IL-17 receptor. The IL-17 pathway plays an important role in inducing and promoting inflammatory disease processes. 

Brodalumab is the first investigational treatment in development that blocks the IL-17 receptor, thereby blocking several of the IL-17 ligands at once. By stopping IL-17 ligands from binding to the receptor, brodalumab prevents the body from receiving signals that may lead to inflammation and other ailments. At this time, other agents in development seek to target a single IL-17 ligand. 

In addition to psoratic arthritis, brodalumab is currently being investigated for the treatment of psoriasis (Phase 3) and asthma (Phase 2).

About Psoriatic Arthritis

Psoriatic arthritis is a chronic disease of the immune system that causes joint pain, stiffness and swelling which can become progressively worse over time, and may also include red patches of skin topped with silvery scales.1

The progressive joint damage, pain and swelling coupled with painful, scaly, red skin patches can disrupt a person's ability to perform daily activities, such as using their hands, standing for long periods or walking.2 Psoriatic arthritis affects 30 to 50 percent3 of the approximate 125 million people worldwide who have psoriasis.4 

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping people around the world in the fight against serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to drama
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Aethlon Medical, Inc. ... biofiltration devices to treat life-threatening diseases, today announced that ... conference call and webcast on Thursday, August 13, 2015 ... and webcast will follow the release of fiscal 2016 ... will be available approximately two hours after the call ...
(Date:8/3/2015)... -- E-QURE Corp. (OTCQB: EQUR), a Delaware ... Therapy device ("BST Device"), a new and novel electrotherapy ... wounds, today announced that the Company has signed its ... in medical devices, for the marketing and distribution of ... years old, sales, marketing and distribution company in ...
(Date:8/3/2015)... , Aug. 3, 2015   Intrexon Corporation ... release first half and second quarter 2015 financial results ... , 2015.  The Company will host a conference call ... provide a general business update. The conference ... and 1-412-902-4262 (International), and asking to join the "Intrexon ...
(Date:8/3/2015)... According to a new market ... Asia to Witness Highest Growth ... cell culture market was valued at US$ 586.1 Mn in ... of 29.1% to account for US$ 2,717.6 Mn by ... 3D cell culture refers to a ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4
... Corporation (Nasdaq: DNDN ) today announced that management ... in San Francisco on Thursday, January 15, 2009 at 11:00 ... presentation will be accessible through the Investor Relations section of ... to listen to the live webcast, it will be archived ...
... CRANBURY, N.J., Jan. 8 Amicus Therapeutics (Nasdaq: ... J. Barer, Ph.D., to its Board of Directors. ... Officer of Celgene Corporation. As an industry veteran, ... and a reputation as a trusted and respected leader ...
... CAMBRIDGE, Mass. January 7, 2008 Researchers from Harvard ... for the first time, a repulsive quantum mechanical force that ... new nanotechnology applications. , The study, led by Federico Capasso, ... of Engineering and Applied Science (SEAS), will be published as ...
Cached Biology Technology:Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2Researchers measure elusive repulsive force from quantum fluctuations 2
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
(Date:7/31/2015)... 31 de julio de 2015 BGI llevará a ... ) del 22 al 25 de octubre de 2015, ... La conferencia celebra su décimo aniversario este año. Desde ... una de las reuniones anuales más influyentes del mundo ... de las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Evolution Group participated in an international research that has resulted ... fly species. The study also includes new data on the ... sixty million years. The research, published in Nature, was ... over the world and consisted in the analysis of the ...
... Inc. and the Prostate Cancer Foundation today announced they ... Program (for Special Team Amplification of Research), an innovative ... heat in cancer therapy to treat prostate cancer, as ... is being launched for the first phase of research ...
... (November 15, 2007) -- In response to the need ... populations of the threatened staghorn coral, Diego Lirman, Ph.D., ... Rosenstiel School of Marine and Atmospheric Science (RSMAS) have ... of staghorn corals. The goals of the coral ...
Cached Biology News:Genome comparison of 12 fruit fly species 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 3Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 4New south Florida nursery to focus on staghorn corals 2
... the ultimate in utility and flexibility press-to-seal ... the needs of the researcher. They are ... or as sheet material that can be ... isolators are autoclavable and non-cytotoxic and can ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: